NAS
DNLI icon

Nykredit A/S’s Denali Therapeutics DNLI Stock Holding History

Nykredit A/S’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.3K Buy
+1,488
New +$30.6K ﹤0.01% 1553

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nykredit A/S's DNLI Position: Q2 2026 in Review

Nykredit A/S opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 1,488 shares worth $38.3K. The stake represents ﹤0.01% of the portfolio and ranks #1553 among its holdings.

210 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Nykredit A/S held 1,488 shares of Denali Therapeutics worth $38.3K as of Q2 2026.
  • Denali Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Denali Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1553 holding.
  • 210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.